Results 111 to 120 of about 1,457,629 (200)

Thermodynamic characterisation of covalent ligand binding

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6704-6717, November 2026.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman   +4 more
wiley   +1 more source

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR‐T Cell Therapy in Oncology: A Systematic Scoping Review

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

Treatment patterns and outcomes among patients treated with second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia

open access: yes
Next-generation Bruton tyrosine kinase inhibitors (BTKis) are standards of care for chronic lymphocytic leukemia (CLL). This study evaluated demographic and clinical characteristics, real-world treatment patterns, and outcomes among patients treated with
Qianhong Fu   +7 more
core   +1 more source

S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP

open access: yesHemaSphere, 2022
D. J. Kuter   +16 more
doaj   +1 more source

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. [PDF]

open access: yesJ Clin Oncol, 2023
Wang ML   +36 more
europepmc   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini   +19 more
wiley   +1 more source

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY

open access: yesHemaSphere, 2022
J. Woyach   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy